ELABORATION AND USE OF SYNGENIC PRE-CLINICAL MODELS FOR CANCER DRUG DEVELOPMENT

Leidos Biomedical Research, Inc., Frederick MD

Investigators

Abstract

The Division of Cancer Treatment and Diagnosis, NCI is requesting support for the development and/or use of existing syngeneic model systems for the pre-clinical evaluation and testing of anti-cancer agents in the presence of an intact immune system. This is of particular interest for immuno-oncology (I/O) agents which cannot be evaluated in the standard xenograft model systems requiring the use of immunocompromised animals.